Takeda's Zasocitinib Demonstrates Superiority in Psoriasis Phase 3 Trial

Takeda announced new data from three Phase 3 LATITUDE studies for zasocitinib, an oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. Presented at EADV 2026, head-to-head data showed zasocitinib was statistically superior to deucravacitinib across primary and key secondary efficacy endpoints, achieving higher rates of complete skin clearance by week 8. This suggests a potentially more effective treatment option for psoriasis patients.